Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials

Kasperkiewicz M, Adotama P, Tomayko MM, Culton DA. Response to Barnawi et al., "Bullous pemphigoid in the era of immunotherapy: Implications for treatment algorithms". J[...]

Zhang H, Patrick MT, Sarkar MK, Bogle R, Li Q, Uppala R, Perez White BE, Petukhova L, Dand N, Stuart PE, Christiano AM, Simpson MA,[...]

Podolsky AS, Singal A, Goh C, Lipner SR. Increased risk of spontaneous abortion risk with alopecia areata independent of antiphospholipid syndrome and endometritis. J Am[...]